Detalhe da pesquisa
1.
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Invest New Drugs
; 42(1): 127-135, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38270822
2.
Participant Evaluation of a Multi-disciplinary Oncology Preceptorship Training Program for Oncology Health Professionals from Kumasi, Ghana.
J Cancer Educ
; 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38506985
3.
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
Blood
; 127(22): 2711-22, 2016 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26917778
4.
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
Blood
; 119(2): 476-87, 2012 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22080480
5.
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
Invest New Drugs
; 31(5): 1251-6, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23543109
6.
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Gynecol Oncol
; 124(2): 210-5, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22047770
7.
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
Nat Commun
; 12(1): 5574, 2021 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34552099